|
Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs). It is being evaluated in clinical trials for various cancer indications. == Mechanisms of action == *Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. *Dinaciclib (SCH727665) inhibits the unfolded protein response (UPR) through a CDK1 and CDK5-dependent mechanism. == Anti-tumoral action == *In melanoma * *The anti-melanoma activity of dinaciclib is dependent on p53 signaling. *In chronic lymphocytic leukemia (CLL) * * Dinaciclib promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. *In pancreatic cancer * *Dinaciclib inhibits pancreatic cancer growth and progression in murine xenograft models. *In osteosarcoma * *Dinacliclib induces the apoptosis of osteosarcoma cells. * *Apoptosis of osteosarcoma cultures can be induced by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Dinaciclib」の詳細全文を読む スポンサード リンク
|